The Limited Times

Now you can see non-English news...

Ema rates ok to Glaxo Xevudy monoclonal therapy

2021-11-18T14:15:57.123Z


(HANDLE) BRUSSELS - The European Medicines Agency (Ema) has started the evaluation of an application for authorization of GlaxoSmithKline for the Covid treatment of adults and adolescents with the monoclonal antibody Xevudy (sotrovimab). It reads in a note from the EMA. The opinion of the EMA could arrive within the next two months. GlaxoSmithKline developed the medicine together with Vir Biotechnology.


BRUSSELS -

The European Medicines Agency (Ema) has started the evaluation of an application for authorization of GlaxoSmithKline for the Covid treatment of adults and adolescents with the monoclonal antibody Xevudy

(sotrovimab).

It reads in a note from the EMA.

The opinion of the EMA could arrive within the next two months.

GlaxoSmithKline developed the medicine together with Vir Biotechnology.

Source: ansa

All news articles on 2021-11-18

You may like

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z
News/Politics 2024-03-28T05:25:00.011Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.